Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

November 30, 2010

Conditions
ThalassemiaHypertension, Pulmonary
Interventions
DRUG

Sildenafil

"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"

Trial Locations (1)

94609

Children's Hospital and Research Institute Oakland, Oakland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Carelon Research

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH